Gimv — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.
BiotechHealthtech
Daniel Olive(Founder)
Co-investorsAgent CapitalAndera PartnersKurma PartnersPfizer Venture InvestmentsPureos BioventuresAlexandria+4 more
SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.
BiotechHealthtechMedical Devices
Ray Barlow(Chief Executive Officer)in
Co-investorsHealthCapBioqube VenturesForbionMedicxi
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.